Texas Oncology

Running trials

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Source

• Recruiting

  Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  NCT07566156· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07266441· Phase 2· Source

• Recruiting

  Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  NCT07287917· Phase 1/2· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Source

• Recruiting

  Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  NCT05972135· Phase 2· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Source

• Active, not recruiting

  A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

  NCT04752813· Phase 2· Source

• Active, not recruiting

  Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

  NCT05074810· Phase 1/2· Source

• Active, not recruiting

  A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

  NCT03561220· Source

• Active, not recruiting

  INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

  NCT03491683· Phase 1/2· Source

• Active, not recruiting

  A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

  NCT02138734· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Head and neck cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06790966· Phase 3· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Source

• Completed

  Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

  NCT03424603· Phase 1· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Source

• Terminated

  A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

  NCT02841540· Phase 1· Source